Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Delays Savella Launch: FDA Reviewing Tablet Color Change

This article was originally published in The Pink Sheet Daily

Executive Summary

Delay not expected to impact long-term sales, analysts predict.

You may also be interested in...



Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas

After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.

Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas

After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.

Offsetting The Pain: Forest Pushes Savella To Dampen A Lexapro Sales Slide

Forest's Savella is gaining 1,200 to 1,300 new prescribers per week and now has a 3.5 percent share of the market for fibromyalgia treatments

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel